TEC与FEC方案在局部晚期乳腺癌新辅助化疗中的疗效对比观察  

Efficacy observation of TEC and FEC schemes in neoadjuvant chemotherapy for locally advanced breast cancer

作　　者：刘莉萍[1] 欧阳取长[1] 曹敏[1] 水峥嵘[1] 

机构地区：[1]湖南省肿瘤医院乳腺内科,湖南长沙410013

出　　处：《现代预防医学》2012年第17期4416-4417,4419,共3页Modern Preventive Medicine

摘　　要：目的对比观察TEC与FEC方案在局部晚期乳腺癌新辅助化疗中的疗效。方法将118例晚期乳腺癌患者随机分为TEC方案组和FEC方案组,每组59例。观察两组的疗效及不良反应。结果 118例患者均接受了4个周期的TEC方案或FEC方案的化疗,TEC方案的总有效率为76.3%,FEC方案的总有效率为64.4%,两组比较差异有统计学意义(P﹤0.05)。两组常见的不良反应为恶心呕吐,脱发,白细胞降低,血小板降低等,TEC方案组的不良反应发生率高于FEC方案组。结论对晚期乳腺癌进行新辅助化疗,TEC方案疗效优于FEC方案,但不良反应较大。临床应根据不同情况选择合理的化疗方案。OBJECTIVE To observe the efficacy of TEC and FEC schemes in neoadjuvant chemotherapy for locally advanced breast cancer.METHODS 118 cases of advanced breast cancer were randomly divided into program groups TEC and FEC program groups,each with 59 cases.The efficacy and adverse reactions were observed.RESULTS 118 patients were treated with 4 cycles of FEC and TEC program or the program of chemotherapy,TEC program,the total effective rate was 76.3%,FEC scheme,the total effective rate was 64.4%,the two groups had a significant difference（P﹤0.05）.Common adverse reactions were nausea,vomiting,hair loss,leukopenia,thrombocytopenia,etc.in two groups.TEC program group had the high incidence of adverse reactions than those of the FEC regimen.CONCLUSION Neoadjuvant chemotherapy for advanced breast cancer,TEC program is more effective than FEC schemes,but more adverse reactions.Different clinical rational chemotherapy should be chosen according to the patients.

关 键 词：局部晚期乳腺癌 化疗 TEC方案 FEC方案 

分 类 号：R453[医药卫生—治疗学] R737.9[医药卫生—临床医学]